2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.. Other regulations The California Assembly voted on Thursday 55-7,) a bill , is aimed at by of the use of machines which may development of the fetus development of the fetus, in their houses could sonograms, the New York Times reports on lead, limiting. FDA does not promote the use of ultrasound outside medical supervision, the Times reports. According to the agency’s website, ‘people, should sell the promotion or lease ultrasound equipment for making ‘ keepsake ‘ fetal videos know that considered FDA such as unauthorized use of a medical device ‘(Marshall, New York Times, The bill now goes to the Senate for consideration (AP / Forbes – ‘courtesy of you, the entire Kaiser Daily Health Policy view Report, search the archives, or sign up for email delivery at Kaiser Daily Health Policy Report strongly supported kaiser network a free service of the Henry J.
Mimetogen Pharmaceuticals Announces Initiation of Phase II Trial of Novel NGF Mimetic in patients with dry eye – Mimetogen Pharmaceuticals Inc. In phase biotechnology company focused on developing novel small molecule drugs that of of neurotrophins concentrated, today announced that it has initiated the first human clinical trial MIM – D3, a mimetic of nerve growth factor . In a phase II clinical trial in patients with moderate to severe dry eye MIM – D3 is a small cyclic peptidomimetic of NGF, a naturally occurring protein. In the eye that maintenance maintenance of corneal nerves and epithelium, mucin and tear production This is an important milestone in the development of Mimetogen, as this study the first the first use of small molecule mimetics of neurotrophins an eye disease treatment Encouraging data from animal models of dry eye to treat treat the use of neurotrophin mimetics dry eye and other degenerative ocular indications such as glaucoma is an important new approach for eye diseases for which there are currently very limited treatment options, said Garth Cumberlidge, Chief Executive Officer of Mimetogen.